Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

Participants in the study may also receive mRNA-4157, which is an intramuscular injection, meaning it is administered directly into a muscle. The study is designed as a randomized and double-blind trial, which means participants are assigned to different treatment groups by chance, and neither the participants nor the researchers know which specific treatment is being given during the course of the study. This approach helps ensure that the results are as objective as possible.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The purpose of this study is to assess how safe and effective the combination of BNT327 and docetaxel is for treating advanced non-small cell lung cancer. The study is designed as a Phase II trial, which means it follows initial safety testing and aims to further evaluate the treatment’s safety while also beginning to measure how well it works against the cancer.

During the study, participants will receive the combination treatment and be monitored for side effects. Doctors will also track how the cancer responds to treatment by measuring whether tumors shrink, remain stable, or continue to grow. Various assessments will be conducted throughout the study to evaluate the treatment’s effectiveness and to monitor participants’ overall health and survival.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of the study is to compare the overall survival of patients receiving these treatments. Participants will receive the medications through an intravenous infusion, which means the drugs are delivered directly into the bloodstream through a vein. The study will be conducted over a period of time, with regular monitoring to assess the effects of the treatment. Participants will be closely observed for any side effects or changes in their condition.

This trial aims to provide valuable information on the potential benefits and risks of these treatments for patients with metastatic squamous NSCLC. By participating in the study, researchers hope to gain insights that could lead to improved treatment options for this type of lung cancer in the future.

Participants in the study will receive either the cancer vaccine or the chemotherapy drug. The cancer vaccine, OSE2101, is given as an injection under the skin, while docetaxel is administered through an intravenous infusion, which means it is given directly into a vein. The study will last for up to 24 months, during which time the health and progress of the participants will be closely monitored by the research team. The main goal is to see which treatment helps patients live longer, regardless of the cause of death.

This study is important for patients with NSCLC who have not responded to previous immune therapy treatments. By comparing the cancer vaccine with chemotherapy, researchers hope to find a more effective treatment option for these patients. The trial will provide valuable information on the safety and effectiveness of OSE2101 compared to docetaxel, potentially leading to better treatment strategies for this type of lung cancer.

The study is divided into three parts. In Part A, patients with advanced solid tumors or lymphomas will receive OSE-279 to determine the best dose. In Part B, the safety and tolerability of the combination of OSE-279 and TEDOPI will be evaluated in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have a specific genetic marker called HLA-A2. In Part C, the effectiveness of the combination treatment will be compared to OSE-279 alone in patients with the same type of lung cancer. The study will involve regular visits to the clinic for treatment and monitoring over a period of time.

Throughout the study, patients will receive either the study medications or a placebo. The study aims to assess how well the treatments work in terms of reducing the size of the tumors and improving the overall response rate. The study will also monitor any side effects experienced by the participants to ensure the treatments are safe. The trial is expected to continue until 2029, with the goal of finding new and effective treatment options for these types of cancer.

The purpose of this study is to compare two different ways of giving pembrolizumab: as a subcutaneous injection (under the skin) and as an intravenous infusion (through a vein). Participants will receive pembrolizumab along with one of the chemotherapy drugs as part of their first-line treatment, which means it is the first treatment given for their cancer. The study will help determine how the body processes pembrolizumab when given in these two different ways and will also look at the safety of these treatments.

Participants in the study will receive treatment over a period of time, with regular visits to the clinic for their medication and monitoring. The study will track how well the cancer responds to the treatment and any side effects that may occur. This information will help doctors understand the best way to use pembrolizumab in combination with chemotherapy for treating metastatic non-small cell lung cancer.

The purpose of the study is to compare the effectiveness of Pembrolizumab combined with Olaparib against Pembrolizumab combined with a placebo in treating this type of lung cancer. The study aims to see how these treatments affect the time patients live without the cancer getting worse and their overall survival. Participants will receive the treatments over a period of time, and their health will be monitored to assess the effects of the medications.

Throughout the study, participants will receive regular check-ups and assessments to monitor their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on the potential benefits and risks of using these medications in combination for treating Metastatic Squamous Non-small Cell Lung Cancer.

The purpose of the study is to see if adding Retifanlimab to the chemotherapy regimen can improve the overall survival of patients compared to chemotherapy alone. Participants in the study will be randomly assigned to receive either the combination of Retifanlimab and chemotherapy or a placebo and chemotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased.

Throughout the study, participants will receive their assigned treatments through intravenous infusions, which means the medication is given directly into a vein. The study will monitor participants over a period of time to assess their response to the treatment and any side effects they may experience. The goal is to determine if the new treatment combination can help patients live longer and improve their quality of life.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.